# Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers

> **NCT01594515** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 70 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1015550
- **DRUG:** BI 1015550
- **DRUG:** BI 1015550
- **DRUG:** BI 1015550
- **DRUG:** BI 1015550
- **DRUG:** Placebo
- **DRUG:** BI 101550
- **DRUG:** BI 1015550
- **DRUG:** BI 1015550
- **DRUG:** BI 1015550

## Key facts

- **NCT ID:** NCT01594515
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01594515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01594515, "Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01594515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*